Under the deal, B. Braun will market TissuGlu through its Closure Technologies sales team. Cohera has been marketing the product directly in Germany since 2012, according to a press release.
TissuGlu is approved in Europe for use in “large-flap” surgical procedures such as abdominoplasties and mastectomies. The FDA issued an approvable letter for the product in early January.
“Cohera is excited to enter the relationship with B. Braun for the marketing of TissuGlu in these European countries,” CEO Patrick Daly said in a statement. “We are looking forward to working with such a great organization and to making our breakthrough TissuGlu product available to more surgeons and patients in Europe.”
Cohera announced in December that it won priority review status from the FDA for its surgical sealant Sylys because it addresses an unmet medical need. The product is used to prevent anastomotic leaks in patients undergoing gastrointestinal surgery.